Abstract
Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Current Pharmaceutical Design
Title: Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Volume: 17 Issue: 18
Author(s): Sylvia S. Singh and Peter M. Kang
Affiliation:
Keywords: Apoptosis, Heart failure, Caspase inhibitors, Endogenous inhibitors, Anti-apoptotic interventions, Caspase, Endogenous, zymogens, Cardiovascular, congestive, executioner, hypertrophy, diabetes, systolic, reperfusion, myocardial, mitochondrial, proteases
Abstract: Apoptosis or progress of programmed cell death is a tightly regulated process which plays an important role in various cardiovascular diseases particularly in myocardial infarction, reperfusion injury, and heart failure. Over the past two decades, investigations of several pathways have broadened our understanding of programmed cell death. Many anti-apoptotic interventions have targeted ischemia- reperfusion, however only a limited number have been considered at the chronic stage of heart failure. Endogenous inhibitors, caspase inhibitors, PARP-1 inhibitors, as well as various other agents have been implicated as anti-apoptotic interventions. This review summarizes the apoptotic pathways associated with heart failure, discusses the current anti-apoptotic interventions available and reviews the clinical implications.
Export Options
About this article
Cite this article as:
S. Singh Sylvia and M. Kang Peter, Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases, Current Pharmaceutical Design 2011; 17 (18) . https://dx.doi.org/10.2174/138161211796390994
DOI https://dx.doi.org/10.2174/138161211796390994 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Forkhead Genes: Their Role and Impact on Ocular Developmental Diseases
Current Genomics Stem Cell Based Tissue Engineering and Regenerative Medicine: A Review Focusing on Adult Stem Cells
Current Tissue Engineering (Discontinued) Donor-transmitted Anterior Myocardial Ischaemia in a Teenager: How to Proceed?
New Emirates Medical Journal Mechanism of Oxidative Broncho-Epithelial Cell Damage with Reference to Gas Phase Cigarette Smoke
Mini-Reviews in Organic Chemistry Autonomic Dysfunction and Depression: A Biomarker of MDD Across the Life Span
Current Psychiatry Reviews Editorial from Editor-in-Chief: Amniotic Pulmonary Embolism and the Respiratory System: Management Trends and Future Options
Current Respiratory Medicine Reviews Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Incretin-Based Therapies in Patients with Type 2 Diabetes
Current Drug Therapy Growth Hormone Secretagogue (Ghrelin-) Receptors - A Complex Drug Target for the Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Genetics of Atherosclerosis in Murine Models
Current Drug Targets New Technologies for the Diagnosis of Sleep Apnea
Current Hypertension Reviews Synthesis and Biological Properties of Dihydro-Oxadiazine-Based Heterocyclic Derivatives
Mini-Reviews in Medicinal Chemistry Hypocholesterolemia
Current Vascular Pharmacology The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Treatment Failure in Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Fatty Liver and Ischemia/Reperfusion: Are there Drugs Able to Mitigate Injury?
Current Medicinal Chemistry Mesenchymal Stem Cells: Promising for Myocardial Regeneration?
Current Stem Cell Research & Therapy Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
Mini-Reviews in Medicinal Chemistry Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design